Cargando…
Preclinical Evidence of the Efficacy of Lewis Y Car T Cells in Patient-Derived Models of Prostate Cancer
Chimeric antigen receptor T (CAR T) cell therapy is an adoptive immunotherapy that has led to new treatments for lymphoma, leukemia, and other blood cancers; however, its efficacy for prostate cancer remains unproven. Here we report pre-clinical evidence of the efficacy of CAR T cell therapy against...
Autores principales: | Risbridger, Gail Petuna, Porter, Laura Helen, Zhu, Joe, Byrne, David, Lister, Natalie, Azad, Arun, Hofman, Michael, Vela, Ian, Taylor, Renea A, Neeson, Paul, Darcy, Phil, Trapani, Joseph |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089198/ http://dx.doi.org/10.1210/jendso/bvab048.2106 |
Ejemplares similares
-
SAT-330 Preclinical Screen of Patient CRPC Tumors Shows Sensitivity to Bromodomain Inhibitors Includes AR-null and Neuroendocrine Disease
por: Risbridger, Gail, et al.
Publicado: (2019) -
Low-dose carboplatin modifies the tumor microenvironment to augment CAR T cell efficacy in human prostate cancer models
por: Porter, L. H., et al.
Publicado: (2023) -
Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer
por: Perera, Mahasha P.J., et al.
Publicado: (2022) -
To target or not to target the enemy within localized prostate cancer
por: Risbridger, Gail, et al.
Publicado: (2013) -
Challenges of PD-L1 testing in non-small cell lung cancer and beyond
por: Wang, Minyu, et al.
Publicado: (2020)